ATRA— Atara Biotherapeutics, Inc.

FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Atara Biotherapeutics GAAP EPS of $2.61 beats by $4.06, revenue of $120.8M

Atara Biotherapeutics: Q4 Earnings Snapshot

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Pierre Fabre seeks to revive US approval chances for spurned cell therapy